Literature DB >> 31534959

Retracted: Treatment of Acute Pulmonary Embolism: Update on Newer Pharmacologic and Interventional Strategies.

.   

Abstract

[This retracts the article DOI: 10.1155/2014/410341.].

Entities:  

Year:  2019        PMID: 31534959      PMCID: PMC6724442          DOI: 10.1155/2019/4217864

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


BioMed Research International has retracted the article titled “Treatment of Acute Pulmonary Embolism: Update on Newer Pharmacologic and Interventional Strategies” [1]. The article was found to contain a substantial amount of material, without citation, from previously published articles, including the following sources: William T. Kuo. “Endovascular Therapy for Acute Pulmonary Embolism”, Journal of Vascular and Interventional Radiology, 2012. https://doi.org/10.1016/j.jvir.2011.10.012. [2] Peter H. Lin, Huiting Chen, Carlos F. Bechara, and Panagiotis Kougias. “Endovascular Interventions for Acute Pulmonary Embolism”, Perspectives in Vascular Surgery and Endovascular Therapy, 2010. (http://journals.sagepub.com/doi/10.1177/1531003510379880). [3] Mitchell J. Daley, and Ishaq Lat. “Clinical Controversies in Thrombolytic Therapy for the Management of Acute Pulmonary Embolism”, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, 2012. https://doi.org/10.1002/PHAR.1051. [4] Michael R. Jaff, M. Sean McMurtry, Stephen L. Archer, Mary Cushman, Neil Goldenberg, Samuel Z. Goldhaber, J. Stephen Jenkins, Jeffrey A. Kline, Andrew D. Michaels, Patricia Thistlethwaite, Suresh Vedantham, R. James White, Brenda K. Zierler, and on behalf of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Peripheral Vascular Disease, and Council on Arteriosclerosis, Thrombosis and Vascular Biology, “Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association”, Circulation, vol. 123, no. 16. (https://www.ahajournals.org/doi/full/10.1161/CIR.0b013e318214914f) https://doi.org/10.1161/CIR.0b013e318214914f. [5] David F. Allie, Chris J. Hebert, Raghotham R. Patlotla, Agostino Ingraldi, and Craig M. Walker: “Contrast-Induced Nephropathy & Targeted Renal Therapy During Peripheral Vascular Interventions: Results of the Louisiana Targeted Renal Therapy in Critical Limb Ischemia (TRT-CLI) Registry”, American Journal of Cardiology, Volume 104, Issue 6, p. 198D, article TCT-535. https://doi.org/10.1016/j.amjcard.2009.08.571. [6]
  5 in total

1.  Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association.

Authors:  Michael R Jaff; M Sean McMurtry; Stephen L Archer; Mary Cushman; Neil Goldenberg; Samuel Z Goldhaber; J Stephen Jenkins; Jeffrey A Kline; Andrew D Michaels; Patricia Thistlethwaite; Suresh Vedantham; R James White; Brenda K Zierler
Journal:  Circulation       Date:  2011-03-21       Impact factor: 29.690

Review 2.  Endovascular interventions for acute pulmonary embolism.

Authors:  Peter H Lin; Huiting Chen; Carlos F Bechara; Panagiotis Kougias
Journal:  Perspect Vasc Surg Endovasc Ther       Date:  2010-09

Review 3.  Clinical controversies in thrombolytic therapy for the management of acute pulmonary embolism.

Authors:  Mitchell J Daley; Ishaq Lat
Journal:  Pharmacotherapy       Date:  2012-02       Impact factor: 4.705

Review 4.  Endovascular therapy for acute pulmonary embolism.

Authors:  William T Kuo
Journal:  J Vasc Interv Radiol       Date:  2011-12-20       Impact factor: 3.464

Review 5.  Treatment of acute pulmonary embolism: update on newer pharmacologic and interventional strategies.

Authors:  Francesco Pelliccia; Michele Schiariti; Claudio Terzano; Abdul M Keylani; Darrin C D'Agostino; Giuseppe Speziale; Cesare Greco; Carlo Gaudio
Journal:  Biomed Res Int       Date:  2014-06-15       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.